期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
充血性心力衰竭合并室性心早搏患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清BNP的影响分析 被引量:9
1
作者 朱鼎粤 《吉林医学》 CAS 2019年第5期936-938,共3页
目的:分析充血性心力衰竭(CHF,简称心衰)合并室性心早搏(PVC)患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清B型钠尿肽(BNP)的影响。方法:选择84例CHF合并PVC患者为研究主体,分为试验组和对照组,各为42例。试验组给予厄贝沙坦+比索洛... 目的:分析充血性心力衰竭(CHF,简称心衰)合并室性心早搏(PVC)患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清B型钠尿肽(BNP)的影响。方法:选择84例CHF合并PVC患者为研究主体,分为试验组和对照组,各为42例。试验组给予厄贝沙坦+比索洛尔治疗,对照组给予常规治疗。对比两组的临床疗效。结果:试验组的治疗总有效率为97.62%,对照组为83.33%,两组对比差异有统计学意义(P<0.05)。试验组的血清BNP(B型钠尿肽)与室性早搏数均低于对照组,两组对比差异有统计学意义(P<0.05)。治疗后,两组的各项心功能指标均优于治疗前,且试验组优于对照组,组间与组内对比差异有统计学意义(P<0.05)。试验组的不良反应发生率为7.14%,对照组为11.90%,对比差异无统计学意义(P>0.05)。结论:为CHF合并PVC患者行厄贝沙坦+比索洛尔治疗的效果较佳,可改善血清BNP水平和心功能指标,减少室性早搏次数,且不良反应较少,具有较高的应用价值。 展开更多
关键词 充血力衰竭 室性心早搏 厄贝沙坦 比索洛尔 血清B型钠尿肽
下载PDF
充血性心衰合并室性早搏患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清BNP的影响分析 被引量:1
2
作者 朱鼎粤 《心血管病防治知识(学术版)》 2019年第12期42-44,共3页
目的分析充血性心衰(CHF)合并室性心早搏(PVC)患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清BNP的影响。方法选择本院于2017年3月至2018年5月间收治的84例CHF合并PVC患者为研究主体。划分为A组和B组,均是42例。A组给予厄贝沙坦+比索... 目的分析充血性心衰(CHF)合并室性心早搏(PVC)患者实施厄贝沙坦联合比索洛尔治疗效果及其对血清BNP的影响。方法选择本院于2017年3月至2018年5月间收治的84例CHF合并PVC患者为研究主体。划分为A组和B组,均是42例。A组给予厄贝沙坦+比索洛尔治疗,B组给予常规治疗。对比临床疗效。结果 A组的治疗总有效率为97.62%,B组为83.33%,对比差异有统计学意义(P<0.05)。治疗后,两组的血清BNP(B型钠尿肽)均低于治理前,且A组低于B组,组间与组内对比差异有统计学意义(P<0.05)。A组的室性早搏数低于B组,对比差异有统计学意义(P<0.05)。治疗后,两组的各项心功能指标均优于治疗前,且A组优于B组,组间与组内对比差异有统计学意义(P<0.05)。A组的不良反应发生率为7.14%,B组为11.90%,对比差异无统计学意义(P>0.05)。结论为CHF合并PVC患者行厄贝沙坦+比索洛尔治疗的效果较佳,可改善血清BNP水平和心功能指标,减少室性早搏次数,且不良反应较少,具有较高的应用价值。 展开更多
关键词 充血 室性心早搏 厄贝沙坦 比索洛尔 血清BNP
下载PDF
A Chinese Compound Prescription Ding Xin Recipe Combined with Amiodarone for Treating Premature Ventricular Complexes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial 被引量:1
3
作者 Feng-Hua ZHOU Yu-Hua JIA +5 位作者 Sui-Lin YE Lin-Jie LOU Ping YANG Jie LI Yue-Jun ZHANG Rong-Jiang QIAN 《Digital Chinese Medicine》 2018年第1期56-66,共11页
Objective To evaluate the efficacy and safety of Ding Xin Recipe(DXR)combined with amiodarone in patients with PVCs.Methods A total of360patients with PVCs across7centers in China were randomly assigned in a1:1:1ratio... Objective To evaluate the efficacy and safety of Ding Xin Recipe(DXR)combined with amiodarone in patients with PVCs.Methods A total of360patients with PVCs across7centers in China were randomly assigned in a1:1:1ratio to receive up to8weeks of amiodarone combined with DXR placebo(amiodarone group),DXR combined with amiodarone placebo(DXR group),or DXR combined with amiodarone(DCA group)from July2012to December2013.Randomization was conducted according to a centralized randomization schedule prepared by an independent steering committee.Staff and patients at all sites were masked to treatment allocation.All patients received best-evidence advice.The primary outcome was the efficacy for treating PVCs,with efficacy assessed by the reduction of premature ventricular contractions.Other outcome measures included PVCs-related symptom scores.All data were analyzed by intention to treat.Results The efficacy for treating PVCs in the DCA group(90.7%)significantly increased compared with that in the amiodarone group(72.3%)and the DXR group(73.9%).The frequency,the degree,and the duration per week of heart palpitations,chest tightness,shortness of breath and fatigue improved significantly in the DCA group in comparison with the amiodarone group and the DXR group(P<0.05),while no significant difference was observed in the improvement of insomnia among the three groups(P>0.05).With regard to laboratory parameters for safety,there were no clinically relevant changes in the three groups.Conclusion The present study demonstrates that DXR combined with amiodarone is significantly more effective than DXR or amiodarone alone for treating PVCs. 展开更多
关键词 Remae ventricular complexes AMIODARONE Ding Xin Recipe Safety Clinical trial
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部